Posted inAllergy & Immunology Dermatology news
Feasibility and Comparative Outcomes of 24-Week Abrocitinib Tapering in Moderate-to-Severe Atopic Dermatitis
This study evaluates the successful 24-week tapering of abrocitinib in moderate-to-severe atopic dermatitis patients, comparing dose reduction versus interval extension tapering regimens and demonstrating high feasibility with substantial dose and cost reductions.